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Ab s t r a c t
Introduction: Venom allergy, though rare, may seriously influence health-relat-
ed quality of life (HRQoL). There is a paucity of research on HRQoL of adoles-
cents and young adults with Hymenoptera venom allergy. The aim was to assess
the level of HRQoL and to evaluate its independent predictors in Polish ado-
lescents and young adults treated with venom immunotherapy.
Material and methods: A multicenter cross-sectional study based on the Vespid
Allergy Quality of Life Questionnaire (VQLQ) adapted for Polish adolescents was
used. The study sample included 87 patients (14-21 years) studied at different
stages of venom immunotherapy (VIT). Statistical analysis was done with mul-
tivariate linear regression. 
Results: Anxiety level was higher in patients with 4th grade of Mueller’s classi-
fication (anaphylactic shock) than in those with 3rd grade (B = 0.84, 95% CI =
0.07-1.61, p = 0.03). Caution increased along with an increase of anxiety of ado-
lescents treated with VIT (B = 0.54, 95% CI = 0.39-0.68, p < 0.01). Level of lim-
itations increased with increasing caution of adolescents (B = 0.63, 95% CI =
0.35-0.91, p < 0.01). Discomfort increased along with a rise of caution of patients
(B = 0.38, 95% CI = 0.22-0.55, p < 0.01). Similarly, it increased with an increase
of their feeling of limitations (B = 0.37, 95% CI = 0.23-0.51, p < 0.01). The level
of discomfort in adolescents treated with VIT was lower in those who were treat-
ed with conventional protocol in comparison to those treated with rush or ultra-
rush ones (B = –0.47, 95% CI = –0.90 - –0.03, p = 0.04).
Conclusions: Severity of anaphylactic reaction is an independent determinant
of anxiety level in adolescents treated with VIT. The VIT protocol affects HRQoL
of treated patients.
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burden.
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Introduction
Hymenoptera venom allergy (HVA), though rare,
is a potentially life-threatening disorder, which
requires a high level approach, appropriate to aller-
gy intensity. Mueller’s four-grade classification
of systemic reactions to insect stings includes gen-
eral urticaria (grade I), angioedema (grade II), stri-
dor or wheezing (grade III) and anaphylactic shock
(grade IV). Subcutaneous injections of venom
immunotherapy (VIT) are a treatment of choice for
patients with grades III and IV. In patients with
grades I and II, additional factors, such as high expo-
sure to venoms or impaired health-related quality
of life (HRQoL) due to venom allergy, are taken into
consideration before making a decision of VIT intro-
duction. The VIT procedure consists of two phases:
the incremental dose phase and the maintenance
dose phase. The incremental dose phase employs
different protocols, which allow for achieving
the maintenance dose phase from within 12 weeks
(conventional) to a few days (rush) or a few hours
(ultra-rush). The maintenance dose is given every
4-6 weeks usually for 3-5 years [1, 2]. 
The impact of insect venom allergy on HRQoL
may be associated with several social restrictions
and limitations in everyday activities of adolescents.
These social limitations influenced by health con-
ditions also trigger changes in psychological well-
being: fear, anxiety, uncertainty and loss of safety
can be expected as a risk of insect venom allergy
consequences. The extent to which psychosocial
consequences of allergy are a burden to adolescent
patients may be influenced by sociodemographic
(e.g. gender, age or place of residence) or medical
(e.g. grade of anaphylactic reaction or VIT duration)
factors (Figure 1).
Several instruments have been developed to
measure HRQoL in children and adolescents 
suffering from different health conditions including
allergic diseases [3-9]. However, the spectrum
of HRQoL scales addressed to adolescents is still
outnumbered by scales addressed to adult patients
[10-13]. 
To assess HRQoL in adult patients with yellow
jacket (Vespula) allergy, the Vespid Allergy Quality
of Life Questionnaire (VQLQ) was developed [14].
The presented results come from the first multi-
center study conducted with adaptation of VQLQ
for Polish adolescents treated with VIT [15]. 
The aim of the study was to assess HRQoL in
adolescents and young adults with yellow jacket or
honey bee allergy, treated with VIT in Poland, and
to evaluate the impact of demographic, social and
medical factors on patients’ HRQoL.
Material and methods
Patient recruitment
The study sample consisted of 87 adolescents
and young adults, aged from 14 to 21 years (mean
age: 17.0 years, SD 2.1 years), who were treated
with VIT in September of 2008 in five clinical cen-
ters in Poland, covering almost the whole popula-
tion at this age treated with VIT in Poland at that
time. Patients were included in the study after com-
pletion of the written consent form by themselves
and by one of their parents. The study was approved
by the Ethics Committee of Jagiellonian University
(number of decision: KBET no. 67/L/2007). The char-
acteristics of the group are listed in Table I.
Measures
Face-to-face interviews were conducted using
a structured questionnaire containing demograph-
ic data, and the adaptation of VQLQ for Polish ado-
lescents. Vespid Allergy Quality of Life Question-
naire is a tool consisting of 14 items concerning
Discomfort
Field sting provoking
allergic reaction
Fear of re-sting
Limitations
CautionGender
Age
Place of residence
Grade of anaphylactic
reaction
Kind of venom
VIT duration
Figure 1. Model of the study 
Solid lines represent both 1. hypothetical medical factors which may influence the level of HRQoL and 2. the hypothesized relationship
between particular dimensions of HRQoL. Dashed lines represent the hypothetical impact of confounding variables on the level of par-
ticular dimensions of HRQoL. 
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the following: anxiety of being stung by insects,
behaviors to avoid further stinging (caution), limi-
tations in outdoor activities during summer and
feeling of being troubled by looking for insects in
different settings (discomfort) [15]. Every item has
a 7-point Likert response scale. Scores of particular
subscales were computed as the algebraic mean
of its items, resulting in scores ranging from 
1 (reflecting the lowest level of measured latent
variables) to 7 (reflecting the highest one: highest
anxiety, highest caution, etc). 
Gender of patients, age and place of residence
were treated as potential socio-demographic pre-
dictors of HRQoL. Due to a relatively small number
of girls in the study sample, and different patterns
of relationship between dimensions of quality of life
and age observed in boys, these two sociodemo-
graphic variables were combined into one cross-
product variable indicating differences between
younger boys (aged 17 years and less) and older
boys (aged 18 years and more) in relation to girls
(irrespectively of their age), treated as the reference
category for this variable. Place of residence was
used as a binary variable differentiating those liv-
ing in villages from those living in towns as the ref-
erence category.
Medical factors, such as kind of culprit insect,
incremental dose protocol and grade of clinical reac-
tion after being stung, were used as dummy vari-
ables. Namely the treatment against wasp venom,
rush protocol and 3rd grade of Mueller’s classifica-
tion were taken as respective reference categories.
Four patients treated with VIT against both venoms
were included in the wasp venom treated group. 
Such variables as age of patients, age at first
sting, number of stings before VIT, age at VIT intro-
duction, and duration of VIT were also tested as
potential predictors of HRQoL and used in the ana -
lysis as continuous variables. 
Statistical analysis
Mean and SD for normal distributions of con-
tinuous variables, or otherwise the median and
quartiles, were used. Comparison of distributions
of variables measured at ordinal or interval level
was done with the Mann-Whitney test when two
groups were compared, and with the Jonckheere-
Terpstra test otherwise. Strength of association
between variables measured at ordinal or interval
level was measured with the Kendall tau-b corre-
lation coefficient.
Assessment of determinants of HRQoL in every
dimension was done with multivariate linear regres-
sion modeling. The results are presented as raw (B)
regression coefficients and 95% CIs. Values of p
lower than 0.05 were treated as statistically signif-
icant. Statistical analysis was conducted with SPSS
15 for Windows. 
Results
Socio-demographic and medical characteristics
The study sample consisted mainly of boys
(83%), and mostly residents of rural areas (63%).
Mean age of adolescents was 17.0 years (SD 2.1
years). The number of patients allergic to either bee
venom or yellow jacket venom was almost equal.
The majority of patients were treated with the rush
protocol and most of them reported 3rd grade
of Mueller’s classification before VIT (Table I).
The patients were studied at different periods
of VIT course, with a median of 3 years of treatment
(Q1 = 1, Q3 = 5). The median age of the first sting was
10 years (Q1 = 7, Q3 = 12) while the median age at
beginning VIT was 13 (Q1 = 12, Q3 = 15). The median
number of stings before VIT was 3 (Q1 = 1, Q3 = 7). 
Univariate analysis
Among the analyzed dimensions of HRQoL,
the highest median was observed for the anxiety
and caution subscales, the lowest for discomfort
(Table II). 
Older boys had significantly lower medians
of anxiety and feeling of limitations than younger
ones and girls (irrespectively of their age). A simi-
lar pattern was noted in caution. Significant differ-
ences in anxiety were observed in relation to sever-
ity of anaphylactic reaction: the median values
Parameter N %
Gender and age
Girls 15 17.2
Younger boys 40 46.0
Older boys 32 36.8
Place of residence
Town 32 36.8
Village 55 63.2
Immunotherapy against
Wasp 40 46.0
Bee 43 49.4
Both 4 4.6
Mueller’s grade before VIT
2 9 10.3
3 54 62.1
4 24 27.6
Protocol
Ultra-rush 16 18.4
Rush 46 52.9
Conventional 25 28.7
Table I. Medical characteristics of the group
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of anxiety increased along with Mueller’s grade.
Higher caution was reported by residents of urban
areas (Table III). 
Multivariate analysis 
The multivariate linear regression model showed
that anxiety increased along with a rise of Mueller’s
grade: in patients with 4th grade (life-threatening
reaction), it was significantly higher than in other
patients. The level of anxiety of adolescents treat-
ed with VIT was lower in older boys than in girls
(irrespectively of their age); however, this difference
was of borderline significance (Table IV).
Caution of adolescents treated with VIT
increased along with an increase of their anxiety 
(B = 0.54, 95% CI = 0.39-0.68, p < 0.01). The differ-
ence in caution between residents of villages and
residents of towns was of borderline significance
(B = –0.44, 95% CI = 0.93-0.04, p = 0.07).
Level of limitations increased along with caution
of adolescents, and it was significantly lower in old-
er boys in comparison to girls, both living in towns;
however, differences between boys regarding place
of residence were not significant (Table V). 
Discomfort increased along with a rise of cau-
tion and the feeling of limitations (B = 0.38, 95% CI
= 0.22-0.55, p < 0.01 and B = 0.37, 95% CI = 0.23-
0.51, p < 0.01, respectively). The level of discomfort
was lower in those who were treated with the con-
ventional protocol in comparison to those treated
with rush or ultra-rush ones (B = –0.47, 95% CI = 
–0.90 - –0.03, p = 0.04).
Discussion
Health-related quality of life in HVA patients is
poorly evaluated. Until the development of VQLQ
by Oude-Elberink, which was the first measurement
tool specific for vespid venom allergic adults, oth-
er attempts had a rather exploratory character 
[1, 14, 16, 17]. The present study is the first part of
multicenter research examining at the same time
Variable Median 1st Quartile 3rd Quartile
Anxiety 3.5 2.5 5.0
Caution 3.5 2.8 4.5
Limitations 3.0 1.0 4.0
Discomfort 2.2 1.3 3.0
Table II. Average levels of particular dimensions 
of quality of life
Variable Median 1st 3rd Value 
Quartile Quartile of p
Anxiety
Gender and age: 
Girls 4.0 3.5 5.0 0.02
Younger boys 4.0 2.5 5.9
Older boys 3.0 2.0 4.0
Mueller’s grade before VIT:
2 3.0 1.5 4.3 0.03
3 3.5 2.5 4.6
4 4.0 3.1 5.9
Caution
Gender and age:
Girls 3.5 3.0 4.5 0.05
Younger boys 4.0 3.0 5.4
Older boys 3.0 2.3 3.7
Place of residence:
Town 3.8 3.1 5.3 0.05
Village 3.3 2.5 4.5
Limitations 
Gender and age:
Girls 3.0 2.0 5.0 0.01
Younger boys 3.0 1.0 5.0
Older boys 2.0 1.0 3.0
Table III. Differences in quality of life level due to ana-
lyzed factors
Variable B Value of p 95% CI for B
Younger boys vs. girls –0.44 0.37 –1.40 0.53
Older boys vs. girls –0.97 0.08 –2.05 0.10
Mueller’s grade: –0.31 0.62 –1.51 0.90
2 vs. 3 (ref.)
Mueller’s grade: 0.84 0.03 0.07 1.61
4 vs. 3 (ref.)
VIT duration (cont.) –0.01 0.09 –0.03 0.00
Table IV. Independent determinants of anxiety
according to multivariate linear regression model
Variable B Value of p 95% CI for B
Younger boys vs. girls –0.31 0.60 –1.47 0.86
Older boys vs. girls –1.57 0.03 –2.98 –0.16
Place of residence: rural 0.33 0.64 –1.06 1.72
vs. urban areas (ref.)
Anxiety 0.17 0.15 –0.06 0.40
Caution 0.63 0.00 0.35 0.91
Younger boys place 0.50 0.54 –1.12 2.11
of residence
Older boys place 1.41 0.12 –0.37 3.19
of residence
Table V. Independent determinants of limitations lev-
el according to multivariate linear regression model
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point HRQoL in almost the entire population of VIT-
treated Polish adolescents. The studies based on
VQLQ were performed in the Netherlands and Eng-
lish-speaking countries; however, up till now VQLQ
has been applied as a unidimensional index and
verification of its multidimensionality is not known
to the authors [14, 18].
The median level of QoL reported by Polish ado-
lescents ranges from 2.2 to 3.5. This suggests that
HRQoL of Polish adolescents, regardless of the kind
of insect causing sensitization, is less impaired than
that of Dutch adults with wasp venom allergy.
Oude-Elberink reports mean scores of the VQLQ
scale of 4.3 in pre-treatment measurements and
4.6 after 1 year of treatment [18]. In another paper,
the same author reported scores of 3.3 in pre-treat-
ment measurements vs. 4.4 after 1 year of treat-
ment in patients who were randomly selected for
treatment with VIT or Epipen adrenaline in autosy-
ringe, reporting improvement in HRQoL in both
groups. A somewhat different situation was report-
ed by patients who decided about VIT treatment
themselves: they reported improvement from 
2.8 to 4.3 after 1 year of treatment [19]. 
The results of factor analysis suggesting multi-
dimensionality of the scale [15, 20] are supported
by the results of linear regression multivariate 
models presented in this study, which resembles
the results obtained in a study using adaptation
of VQLQ for Polish children [21]. The multivariate
models revealed social and medical factors influ-
encing the scores of analyzed dimensions of HRQoL
in adolescents treated with VIT: significant associ-
ations were revealed between Mueller’s grade
of anaphylactic reaction and anxiety, place of resi-
dence and limitations, as well as between the pro-
tocol of VIT and level of discomfort. 
We observed a deteriorated level of HRQoL,
reflected in an increase of anxiety along with a rise
of Mueller’s grade, reported in the sting history
before treatment. This is not consistent with
the Dutch results, which revealed no correlation
of the VQLQ score with the degree of systemic reac-
tion [18]. It is possible that this effect exists, but
might have been suppressed by “including” anxi-
ety level in the total score of VQLQ. 
An observed significant positive relationship
between anxiety and caution means that higher
anxiety of being stung results in higher care to
avoid it. This result is consistent with the observa-
tion made in samples of Polish children with HVA
and their parents [21]. We also noted a lower level
of caution in adolescents from rural areas. Perhaps
they were more accustomed to the presence
of Hymenoptera, as one third of patients living in
rural areas are bee-keepers family members. 
An observed increase of feeling of limitations
during summer along with a rise of caution indi-
cates that behaviors aimed at avoiding being stung
result in abandonment of different activities. 
Studies conducted in Polish children with HVA did 
not confirm a similar relationship, whereas the
same analysis conducted in their parents showed
a decrease in limitations imposed on their children
along with an increase of parental anxiety, which
may suggest that placing limitations on one’s chil-
dren is a consequence of felt anxiety and the most
obvious way to decrease that feeling [21]. 
We observed a significant difference in the level
of limitations between older boys (aged 18 years and
over) and girls, both living in towns, but such differ-
ences did not exist between adolescents living in
rural areas. It seems to be a combined effect of dif-
ferences regarding the level of risk of being stung
and differences regarding the social context
of changes related to achieving the age of maturity.
The noted significant positive influence of both
caution and limitations on discomfort means that
a higher feeling of discomfort is related to avoid-
ance behaviors, and results in a higher feeling
of limitations. A similar impact of caution on the lev-
el of discomfort was observed in parents of chil-
dren treated with VIT in Poland [21].
We also observed a lower level of discomfort in
patients treated with a longer lasting convention-
al protocol. From the medical point of view, short-
er protocols, though requiring a higher number
of subcutaneous injections in a short time, are safe,
and they allow immunoprotection to be achieved
in a shorter time, and at lower costs, so there is
a rising tendency in health care to use shorter pro-
tocols worldwide, including in Poland [22]. It is also
difficult to explain why a shorter duration of the ini-
tial phase of treatment may increase the feeling
of discomfort expressed as being troubled by look-
ing for insects in different situations. It may sug-
gest that this subscale covers a broader sense
of burden of treatment and disease itself, but also
the necessity of improving the medical information
on advantages of shorter protocols. A similar rela-
tionship between HRQoL, symptoms of disease and
specificity of treatment was also observed in asth-
matic patients [23]. 
In conclusion, we observed the following signif-
icant relationships: impact of anxiety upon caution,
impact of caution upon limitations level, and impact
of both caution and limitations upon discomfort.
These results partly resemble the results of the
study on the HRQoL of children with HVA treated
with VIT and their parents, which showed a signif-
icant impact of anxiety on caution in children and
their parents, whereas in their parents an additional
significant relationship was observed between anx-
iety and limitations imposed by them on their chil-
dren, and between parental caution and discom-
fort [21].
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An observed decrease in the level of anxiety
along with VIT duration needs to be confirmed in
follow-up studies, to verify whether the observed
relationship reflects real improvement in HRQoL or
only a response shift effect. This result also sug-
gests that anxiety seems to be the most important
dimension of HRQoL in adolescents treated with
VIT. 
We did not observe any differences in HRQoL
between patients treated against bee and wasp
stings, indicating that the tool designed for vespid
allergic patients turned out to be useful regardless
of the kind of sensitization. This supports the con-
clusion that problems experienced by all HVA
patients, irrespective of the kind of culprit insect,
have a lot in common. 
The study showed an inverse relationship of bor-
derline significance between VIT duration and lev-
el of anxiety, suggesting that VIT may improve
HRQoL in some dimensions. However, the cross-
sectional design of the study does not let us make
such an interpretation. Differences between ado-
lescents and children, concerning factors influenc-
ing particular dimensions of HRQoL, may reflect real
differences concerning the behavioral or social con-
text of their situation (healthy parents of affected
children vs. affected children or adolescents), but
also may be biased by different characteristics
of the adapted scales used in both studies (factor
structure, reliability, scale ranges and distribution,
sensitivity for different confounding factors).
Previous studies of HRQoL in patients with HVA
are limited to adults. The results of studies con-
ducted in adolescents with food allergy suggest that
this age group may differ from others with regard
to risk-taking and coping strategies [24]. The esti-
mation of a serious decrease in HRQoL due to ven-
om allergy may justify the introduction of specific
venom immunotherapy in certain patients with less
severe systemic reactions (urticaria, angioedema).
Up till now, the decision about the VIT protocol has
depended only on medical factors [25]. The present
results confirm the need to conduct such studies
and use of such sophisticated tools for measuring
HRQoL in this group of patients.
In conclusion, place of residence influences
HRQoL in Hymenoptera allergic adolescents. Sever-
ity of anaphylactic reaction is an independent deter-
minant of anxiety level in adolescents treated with
VIT. The VIT protocol influences HRQoL of treated
patients.
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